Immunological outcomes between Tenofovir versus Zidovudine-based regimens: a retrospective cohort study

Abstract

Background: Since 2013, Tenofovir (TDF) and Zidovudine (AZT) based regimen are alternatively used as a fi rst line for treatment of HIV in Tanzania. CD4+ cells count, which is recommended after every six months monitors the immunological progression, and used as one of the indicators of treatment progression. However, there is little literature available information to compare the immunological outcomes of these two regimens.